DesCAARTes™ Phase 1 Trial

Overview
DesCAARTes™ Phase 1 Trial
Expanded Access Policy

DesCAARTes™

Clinical Trial

A Phase 1 Study of Autologous Desmoglein 3 Chimeric Autoantibody Receptor T Cells (DSG3-CAART) in Mucosal Pemphigus Vulgaris, Sponsored by Cabaletta Bio, Inc.

Recruiting Eligible Patients at U.S. Sites

Interested in learning more about the study?

DesCAARTes™

Clinical Trial

Recruiting Eligible Patients at U.S. Sites

Interested in speaking with someone about the study?+